B. De Valk

2.3k total citations
11 papers, 335 citations indexed

About

B. De Valk is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, B. De Valk has authored 11 papers receiving a total of 335 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 4 papers in Pulmonary and Respiratory Medicine and 2 papers in Genetics. Recurrent topics in B. De Valk's work include HER2/EGFR in Cancer Research (3 papers), Cancer Treatment and Pharmacology (3 papers) and Breast Cancer Treatment Studies (2 papers). B. De Valk is often cited by papers focused on HER2/EGFR in Cancer Research (3 papers), Cancer Treatment and Pharmacology (3 papers) and Breast Cancer Treatment Studies (2 papers). B. De Valk collaborates with scholars based in Netherlands, Poland and United Kingdom. B. De Valk's co-authors include Joannes J.M. Marx, Ruben S. G. M. Witlox, Yvonne T. van der Schouw, Paul N. Mainwaring, Ava Kwong, Katarína Petráková, Ian E. Smith, Christoph Thomssen, H. Cortés-Funes and Daniil Stroyakovskiy and has published in prestigious journals such as Journal of Clinical Oncology, The FASEB Journal and British Journal of Cancer.

In The Last Decade

B. De Valk

11 papers receiving 319 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
B. De Valk Netherlands	5	148	95	90	89	51	11	335
André Viveiros Austria	12	222 1.5×	109 1.1×	184 2.0×	56 0.6×	35 0.7×	24	517
Gavin Willis United Kingdom	15	227 1.5×	191 2.0×	165 1.8×	94 1.1×	60 1.2×	24	556
Paula S. Howes United States	7	258 1.7×	151 1.6×	119 1.3×	23 0.3×	51 1.0×	9	451
Rumi Mifuji Japan	7	178 1.2×	132 1.4×	81 0.9×	71 0.8×	45 0.9×	9	476
Hideki Yamaya Japan	12	266 1.8×	188 2.0×	106 1.2×	26 0.3×	61 1.2×	28	625
Galina Shamayeva United States	9	344 2.3×	205 2.2×	147 1.6×	25 0.3×	76 1.5×	16	549
Michael E. Callender United Kingdom	8	53 0.4×	42 0.4×	87 1.0×	22 0.2×	65 1.3×	9	381
Claus Niederau Germany	10	72 0.5×	60 0.6×	77 0.9×	68 0.8×	66 1.3×	18	358
G. Savage United Kingdom	11	108 0.7×	79 0.8×	48 0.5×	30 0.3×	85 1.7×	19	314
Konstantin Gurevich United States	6	156 1.1×	65 0.7×	58 0.6×	13 0.1×	30 0.6×	8	399

Countries citing papers authored by B. De Valk

Since Specialization

Citations

This map shows the geographic impact of B. De Valk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B. De Valk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B. De Valk more than expected).

Fields of papers citing papers by B. De Valk

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by B. De Valk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B. De Valk. The network helps show where B. De Valk may publish in the future.

Co-authorship network of co-authors of B. De Valk

This figure shows the co-authorship network connecting the top 25 collaborators of B. De Valk. A scholar is included among the top collaborators of B. De Valk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with B. De Valk. B. De Valk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Punt, Cornelis J.A., Marinde J. G. Bond, Karen Bolhuis, et al.. (2023). LBA27 First-line systemic treatment in patients with initially unresectable colorectal cancer liver metastases (CRLM): Overall survival of the phase III CAIRO5 study of the Dutch Colorectal Cancer Group. Annals of Oncology. 34. S1268–S1268. 4 indexed citations

Bond, Marinde J. G., Karen Bolhuis, O. J. L. Loosveld, et al.. (2022). LBA21 FOLFOX/FOLFIRI plus either bevacizumab or panitumumab in patients with initially unresectable colorectal liver metastases (CRLM) and left-sided and RAS/BRAFV600E wild-type tumour: Phase III CAIRO5 study of the Dutch Colorectal Cancer Group. Annals of Oncology. 33. S1389–S1389. 2 indexed citations

Tryfonidis, Konstantinos, Sandrine Marréaud, Hussein Khaled, et al.. (2017). Cardiac safety, efficacy, and correlation of serial serum HER2-extracellular domain shed antigen measurement with the outcome of the combined trastuzumab plus CMF in women with HER2-positive metastatic breast cancer: results from the EORTC 10995 phase II study. Breast Cancer Research and Treatment. 163(3). 507–515. 2 indexed citations

Dirks, Marlou L., Benjamin T. Wall, Gijs H. Goossens, B. De Valk, & Luc J. C. van Loon. (2015). One Week of Bed‐rest Substantially Reduces Muscle Mass and Induces Insulin Resistance in Healthy, Young Males. The FASEB Journal. 29(S1). 2 indexed citations

Smith, Ian E., Jean‐Yves Pierga, Laura Biganzoli, et al.. (2010). First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients. Annals of Oncology. 22(3). 595–602. 81 indexed citations

Nešković‐Konstantinović, Zora, M. Nooij, H. Khaled, et al.. (2007). Safety and efficacy of combined trastuzumab and CMF therapy in women with metastatic breast cancer: EORTC protocol 10995. Journal of Clinical Oncology. 25(18_suppl). 1040–1040. 2 indexed citations

Roozendaal, K. J., et al.. (2003). Alveolar soft-part sarcoma responding to interferon alpha-2b. British Journal of Cancer. 89(2). 243–245. 17 indexed citations

Warmerdam, Fabienne, J. L. G. Blaauwgeers, B. De Valk, & K. J. Roozendaal. (2003). [A gastric signet ring cell carcinoma as the first expression of a breast carcinoma].. PubMed. 147(20). 980–4. 1 indexed citations

Valk, B. De, F.R. Leus, Hieronymus A.M. Voorbij, & Joannes J.M. Marx. (2002). Iron does not bind to the Apo‐B protein of low‐density lipoprotein. European Journal of Clinical Investigation. 32(s1). 17–20. 3 indexed citations

10.

Valk, B. De, Ruben S. G. M. Witlox, Yvonne T. van der Schouw, & Joannes J.M. Marx. (2000). Biochemical expression of heterozygous hereditary hemochromatosis. European Journal of Internal Medicine. 11(6). 317–321. 22 indexed citations

11.

Valk, B. De & Joannes J.M. Marx. (1999). Iron, Atherosclerosis, and Ischemic Heart Disease. Archives of Internal Medicine. 159(14). 1542–1542. 199 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact